By Brad Perrillio Medtronic’s fiscal 4th-quarter sales surge nearly 60% thanks to its buyout earlier this year of Covidien, prompting the medical device company to tighten its earning forecast. Medtronic (NYSE:MDT) today beat the consensus forecast for its fiscal 4th-quarter sales,